期刊文献+

晚期卵巢上皮性癌手术切净率的术前预测评估 被引量:3

晚期卵巢上皮性癌手术切净率的术前预测评估
原文传递
导出
摘要 目的对晚期卵巢上皮性癌手术切净率进行术前评估,以利于新辅助化疗后行中间性肿瘤细胞减灭术,使患者免于不必要的手术。方法回顾性分析2005-2008年在四川省肿瘤医院经手术和病理证实的80例Ⅲ、Ⅳ期上皮性卵巢癌患者术前血清CA125水平,CT或MRI结果及有无腹水从而对理想肿瘤细胞减灭术进行术前评估。14例无法手术的患者进行了新辅助化疗后研究其血清CA125水平对其手术切净率的影响。结果首次手术后进行了理想的肿瘤细胞减灭术者50例,肿瘤大块切除术者16例,14例无法切除者先进行了3个周期新辅助化疗后全部进行了二次手术切除。CA125≤450 kU/L,作为满意肿瘤细胞减灭术的阳性预测值为75%,阴性预测值为40%。12例腹膜弥漫性增厚和有大量腹水存在的患者中,仅4例(33%)实现理想的肿瘤细胞减灭术。结论结合有无腹水、CT或MRI检测结果及血清CA125值可提高理想肿瘤细胞减灭术的预测价值。新辅助化疗有利于控制腹水,提高晚期卵巢上皮性癌的手术切除率,了解肿瘤对化疗方案的敏感性,指导术后辅助化疗方案的选择。
作者 刘红 张国楠
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2009年第10期777-778,共2页 Chinese Journal of Practical Gynecology and Obstetrics
基金 四川省重点医学学科建设项目
关键词 卵巢癌 CA125 理想的肿瘤细胞减灭术 新辅助化疗 ovarian cancer CA125 optimal primary cytoreductive surgery neoadjuvant chemotherapy
  • 相关文献

参考文献3

  • 1Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-analysis [ J ]. J Clin Oncol,2002, 20(5) :1248-1259.
  • 2Gilani MM, Karimi Zarchi M, Ghaemmaghami F, et al. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer [ J ]. Gynecol Oncol ,2007 , 105 (3) :780-783.
  • 3Qayyumn A,Coakley FV,Westphalen AC,et al. Role of CT and MR imaging in predic6ng optimal cytoreduction of newly diagnosedprimary epithelial ovarian cancer[ J ]. Gynecol Oncol,2005, 96(2) :301-306.

同被引文献32

  • 1孙秀华,王瑞斐,徐洋.新辅助治疗晚期卵巢上皮性癌30例临床分析[J].中国肿瘤临床与康复,2006,13(3):239-240. 被引量:2
  • 2Guhekin M, Diribas K, Buru E, et al. Interval debulking in epithe- lial ovarian carcinomas: the past, present and the future [ J ]. Eur J Gynaecol Onco1,2008,19 ( 3 ) :242-245.
  • 3Fotopoulou C, Savvatis K, Steinhaqen E, et al. Primary radical surgery in elderly patients with epithelial ovarian cancer analysis of surgical outcome and long-term survival [ J ]. Int J Gynecol Canc- er,2010,20( 1 ) : 34-40.
  • 4Vander Burg MEL, Van Lent M, Buyse M, et al. The role of in- tervention debulking surgery in advanced epithelial ovarian cancer: an EORTC gynecological cancer Cooperative group study [ J ]. N Engl J Med ,1995,332:629-634.
  • 5Morice P, Dubernard G, Rey A, et al. Results of interval debulking surgery compared with primary debu[king surgery in advanced stage ovarian cancer[ J]. J Am Coil Surg,2003 ,197 :955-963.
  • 6Stuart GC, Kitchener H, Bacon M, et al. The participants of 4th Ovarian Cancer Consensus Conference(OCCC) of the Gynecologic Cancer Intergroup. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference [ J ]. Int J Gynecol Cancer,2011,21:750-755.
  • 7Vergote I, De Wever I, Tjalma W, et al. Interval debulking sur- gery: an alternative for primary surgical debulking [ J ]. Semin Surg Oncol, 2000,19:49-53.
  • 8Vergote I, Leunen K, Amant F. Primary surgery or neoadjuvant chemotherapy in ovarian cancer: What is the value of comparing apples with oranges [ J ]. Gynecol Oncol,2012,124 ( 1 ) : 1 - 2.
  • 9Bristow RE,Tomacmz RS, Armstrong DK, et al. Survival effect of maximal cytoreduetive surgery for advanced ovarian carcinoma dur- ing the platinum era : a meta-analysis. J Clin Oncol, 2002,20 ( 5 ) : 1248-1259.
  • 10Martin P, Sven M, Olaf O, et al. Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer-a prospective multicenter phase II trial (PRIMOVAR) [J]. Oncol Rep,2009, 22(3) :605-613.

引证文献3

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部